Bisphosphonate treatment inhibits the growth of prostate cancer cells

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2602-2608

  Lee, Margaret V ^a   Fong, Eva M ^a   Singer, Frederick R ^a   Guenette, R Sean ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DIPHOSPHONATES; GROWTH INHIBITORS; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0035866791     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bisphosphonates in prostate carcinoma
2. Mechanisms of lytic and blastic metastatic disease of bone
3. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer
4. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
5. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multi-national randomized controlled trial
6. Clodronate decreases the frequency of skeletal metastases in women with breast cancer
7. Zoledronate in the treatment of osteolytic bone metastases
8. 1-Hydroxy-3-(methylpentylamino)-propylidene-1, 1-bisphosphonic acid as a potent inhibitor of squalene synthase
9. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
10. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
11. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate
12. Effects of alendronate and Taxol on PC-3 ML cell bone metastases in SCID mice
13. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
14. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
15. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
16. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
17. Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model
18. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
19. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
20. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
21. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
22. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their anti-resorptive potencies in vitro and in vivo
23. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
24. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
25. Membrane association and targeting of prenylated Ras-like GTPases
26. Human protein tyrosine phosphatase-sigma: Alternative splicing and inhibition by bisphosphonates
27. How does alendronate inhibit protein-tyrosine phosphatases?
28. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo
29. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
30. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
31. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells
32. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
33. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer
34. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis
35. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: Implications for the development of metastatic disease
36. Effect of osteoblast supernatants on cancer cell migration and invasion
37. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
38. The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases
39. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumor-induced hypercalcaemia
40. Pamidronate treatment in patients with tumor-associated hypercalcemia: Pharmacological effects and pharmacokinetics
41. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function
42. Pharmacokinetics of pamidronate in patients with bone metastases
43. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure